Disputation: Amalie Føreid Reinertsen

Doctoral candidate Amalie Føreid Reinertsen at the Department of Pharmacy, Faculty of Mathematics and Natural Sciences, is defending the thesis "Stereoselective Syntheses and Biological Evaluations of Novel Resolvins" for the degree of Philosophiae Doctor.

Time and place: , Auditorium 2, Helga Eng
Amalie Føreid Reinertsen

Trial lecture - time and place

07.06.2024, 10.15, Auditorium 2, Helga Eng

Novel Specialized Pro-Resolving Mediators (SPMs) in drug discovery and clinical trials - from bench to future bedside

Conferral summary

Studier gjennom de siste tre tiår har vist at et høyt inntak av omega-3 fettsyrer bidrar til flere gunstige helseeffekter. De molekylære mekanismene bak disse positive effektene er fortsatt ikke fullstendig gjort rede for. Dette prosjektet har bidratt med ny kunnskap til hvordan omega-3 fettsyrer bidrar positivt til helsen.

Main research findings

Research has revealed that omega-3 polyunsaturated fatty acids, like docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), and n-3 docosapentaenoic acid (DPA), are converted to hydroxylated products in the human body. These products have shown promising results regarding their anti-inflammatory and pro-resolving actions. In-depth knowledge about their biosynthesis and establishment of their exact chemical structure is crucial to better understand their biological properties.

This thesis has contributed with new knowledge about the chemical structure of some novel hydroxylated omega-3 products by utilizing synthetic organic chemistry. These synthetic efforts have enabled cell culture studies and biological experiments in mice to give evidence about their biosynthesis and biological actions. Furthermore, the project has contributed to new information about how these hydroxylated omega-3 fatty acid derivatives prevents the development of uncontrolled inflammation, in addition to demonstrating their anti-bacterial and anti-fungal actions. Altogether, this is of great interest to enable the discovery and development of new anti-inflammatory and anti-microbial therapeutics in the future.

The experimental work has been conducted at the Department of Pharmacy, University of Oslo, and the biological work has been performed by our colleagues in the Serhan group at Harvard Medical School and in the Dalli group at Queen Mary University of London.

Read more (in Norwegian)

Published May 24, 2024 10:00 AM - Last modified June 4, 2024 9:33 AM
E-mail this page

Candidate contact information 

LinkedIn: https://www.linkedin.com/in/amalieforeidreinertsen/

ResearchGate: https://www.researchgate.net/profile/Amalie-Reinertsen

E-mail: a.f.reinertsen@farmasi.uio.no and amaliefreinertsen@gmail.com

Phone: +47 995 45 551

Adjudication committee

Professor emeritus Gudmundur Gunnar Haraldsson, Faculty of Physical Sciences, University of Iceland

Professor Tore Lejon, Department of Chemistry, UiT The Arctic University of Norway

Associate Professor Ida Robertsen, Section for Pharmacology and Pharmaceutical Biosciences, Department of Pharmacy, University of Oslo

Supervisors

Professor Trond Vidar Hansen, Section for Pharmaceutical Chemistry, Department of Pharmacy, University of Oslo

Associate Professor Anders Vik, Section for Pharmacutical Chemistry, Department of Pharmacy, University of Oslo

Scientist PhD Karoline Primdahl, Chemring Nobel AS

Chair of defence

Professor Ragnhild Elisabeth Heimtun Paulsen, Department of Pharmacy, University of Oslo